Annual CFI
$225.80 M
+$814.70 M+138.34%
31 December 2022
Summary:
Mirati Therapeutics annual cash flow from investing activities is currently $225.80 million, with the most recent change of +$814.70 million (+138.34%) on 31 December 2022. During the last 3 years, it has risen by +$814.70 million (+138.34%).MRTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$62.19 M
-$77.73 M-500.42%
30 September 2023
Summary:
Mirati Therapeutics quarterly cash flow from investing activities is currently -$62.19 million, with the most recent change of -$77.73 million (-500.42%) on 30 September 2023.MRTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$207.79 M
-$76.14 M-26.82%
30 September 2023
Summary:
Mirati Therapeutics TTM cash flow from investing activities is currently $207.79 million, with the most recent change of -$76.14 million (-26.82%) on 30 September 2023.MRTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +138.3% | +63.6% | +135.3% |
| 5 y5 years | +228.2% | -796.3% | +218.0% |
MRTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | at high | -131.9% | -44.1% |
Mirati Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$62.19 M(-500.4%) | $207.79 M(-26.8%) |
| June 2023 | - | $15.53 M(-92.0%) | $283.93 M(-23.6%) |
| Mar 2023 | - | $195.15 M(+229.1%) | $371.40 M(+64.5%) |
| Dec 2022 | $225.80 M(-138.3%) | $59.30 M(+325.2%) | $225.80 M(-5312.4%) |
| Sept 2022 | - | $13.95 M(-86.5%) | -$4.33 M(-75.3%) |
| June 2022 | - | $103.01 M(+107.9%) | -$17.57 M(-79.0%) |
| Mar 2022 | - | $49.55 M(-129.0%) | -$83.82 M(-85.8%) |
| Dec 2021 | -$588.90 M(+321.1%) | -$170.84 M(<-9900.0%) | -$588.90 M(+23.4%) |
| Sept 2021 | - | $704.00 K(-98.1%) | -$477.40 M(+15.3%) |
| June 2021 | - | $36.76 M(-108.1%) | -$413.95 M(-12.5%) |
| Mar 2021 | - | -$455.53 M(+667.7%) | -$473.16 M(+238.3%) |
| Dec 2020 | -$139.86 M(-20.6%) | -$59.34 M(-192.5%) | -$139.86 M(+59.9%) |
| Sept 2020 | - | $64.16 M(-385.8%) | -$87.46 M(-68.7%) |
| June 2020 | - | -$22.45 M(-81.6%) | -$279.68 M(+6.3%) |
| Mar 2020 | - | -$122.23 M(+1661.4%) | -$263.16 M(+49.4%) |
| Dec 2019 | -$176.14 M(+20.8%) | -$6.94 M(-94.6%) | -$176.14 M(-24.4%) |
| Sept 2019 | - | -$128.07 M(+2060.7%) | -$232.88 M(+206.2%) |
| June 2019 | - | -$5.93 M(-83.2%) | -$76.06 M(-20.7%) |
| Mar 2019 | - | -$35.21 M(-44.7%) | -$95.89 M(-34.2%) |
| Dec 2018 | -$145.76 M(+1584.9%) | -$63.68 M(-321.4%) | -$145.76 M(+105.2%) |
| Sept 2018 | - | $28.76 M(-211.6%) | -$71.04 M(-17.4%) |
| June 2018 | - | -$25.77 M(-69.7%) | -$86.03 M(+63.8%) |
| Mar 2018 | - | -$85.08 M(-870.4%) | -$52.52 M(+507.1%) |
| Dec 2017 | -$8.65 M(-122.6%) | $11.04 M(-19.8%) | -$8.65 M(+723.1%) |
| Sept 2017 | - | $13.77 M(+77.8%) | -$1.05 M(-16.9%) |
| June 2017 | - | $7.74 M(-118.8%) | -$1.26 M(-52.2%) |
| Mar 2017 | - | -$41.21 M(-321.0%) | -$2.64 M(-106.9%) |
| Dec 2016 | $38.26 M(-175.4%) | $18.64 M(+37.5%) | $38.26 M(-252.4%) |
| Sept 2016 | - | $13.56 M(+113.0%) | -$25.10 M(+17.5%) |
| June 2016 | - | $6.37 M(-2140.1%) | -$21.36 M(+7.1%) |
| Mar 2016 | - | -$312.00 K(-99.3%) | -$19.95 M(-60.7%) |
| Dec 2015 | -$50.75 M(-309.6%) | -$44.71 M(-358.4%) | -$50.75 M(-1410.1%) |
| Sept 2015 | - | $17.30 M(+122.5%) | $3.87 M(-151.6%) |
| June 2015 | - | $7.78 M(-125.0%) | -$7.51 M(-21.1%) |
| Mar 2015 | - | -$31.12 M(-413.9%) | -$9.52 M(-139.3%) |
| Dec 2014 | $24.22 M | $9.91 M(+67.6%) | $24.22 M(-192.8%) |
| Sept 2014 | - | $5.92 M(+2.5%) | -$26.10 M(-9.9%) |
| June 2014 | - | $5.77 M(+120.4%) | -$28.97 M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $2.62 M(-106.5%) | -$26.78 M(-9.1%) |
| Dec 2013 | -$29.47 M(<-9900.0%) | -$40.40 M(-1425.2%) | -$29.47 M(-827.8%) |
| Sept 2013 | - | $3.05 M(-61.7%) | $4.05 M(+60.7%) |
| June 2013 | - | $7.96 M(<-9900.0%) | $2.52 M(+2900.0%) |
| Mar 2013 | - | -$70.00 K(-99.0%) | $84.00 K(+52.7%) |
| Dec 2012 | $55.00 K(-100.3%) | -$6.88 M(-553.0%) | $55.00 K(-99.5%) |
| Sept 2012 | - | $1.52 M(-72.5%) | $11.68 M(-26.4%) |
| June 2012 | - | $5.52 M(-5674.7%) | $15.87 M(-186.0%) |
| Mar 2012 | - | -$99.00 K(-102.1%) | -$18.46 M(+3.2%) |
| Dec 2011 | -$17.88 M(-764.7%) | $4.74 M(-17.1%) | -$17.88 M(-21.2%) |
| Sept 2011 | - | $5.72 M(-119.8%) | -$22.69 M(-15.4%) |
| June 2011 | - | -$28.81 M(-6108.8%) | -$26.82 M(-5617.2%) |
| Mar 2011 | - | $479.50 K(-769.7%) | $486.20 K(-81.9%) |
| Dec 2010 | $2.69 M(-90.0%) | -$71.60 K(-104.5%) | $2.69 M(-31.9%) |
| Sept 2010 | - | $1.58 M(-205.2%) | $3.95 M(-72.7%) |
| June 2010 | - | -$1.50 M(-156.0%) | $14.46 M(+6.8%) |
| Mar 2010 | - | $2.68 M(+125.7%) | $13.54 M(-49.7%) |
| Dec 2009 | $26.95 M(+29.9%) | $1.19 M(-90.2%) | $26.95 M(+16.2%) |
| Sept 2009 | - | $12.09 M(-599.0%) | $23.20 M(-3760.7%) |
| June 2009 | - | -$2.42 M(-115.1%) | -$633.80 K(-105.4%) |
| Mar 2009 | - | $16.09 M(-728.6%) | $11.67 M(-43.7%) |
| Dec 2008 | $20.74 M(+241.6%) | -$2.56 M(-78.2%) | $20.74 M(-220.8%) |
| Sept 2008 | - | -$11.74 M(-218.9%) | -$17.18 M(-152.8%) |
| June 2008 | - | $9.88 M(-60.7%) | $32.54 M(+299.0%) |
| Mar 2008 | - | $25.16 M(-162.2%) | $8.15 M(+34.3%) |
| Dec 2007 | $6.07 M(-117.7%) | -$40.48 M(-206.6%) | $6.07 M(-75.1%) |
| Sept 2007 | - | $37.97 M(-361.8%) | $24.41 M(-213.6%) |
| June 2007 | - | -$14.50 M(-162.8%) | -$21.49 M(+274.1%) |
| Mar 2007 | - | $23.08 M(-204.3%) | -$5.74 M(-83.3%) |
| Dec 2006 | -$34.38 M(-388.3%) | -$22.14 M(+179.4%) | -$34.38 M(+139.4%) |
| Sept 2006 | - | -$7.92 M(-738.8%) | -$14.36 M(+134.0%) |
| June 2006 | - | $1.24 M(-122.3%) | -$6.14 M(+2.7%) |
| Mar 2006 | - | -$5.56 M(+162.1%) | -$5.97 M(-150.1%) |
| Dec 2005 | $11.92 M(-215.7%) | -$2.12 M(-808.1%) | $11.92 M(-15.1%) |
| Sept 2005 | - | $299.40 K(-78.6%) | $14.04 M(+2.2%) |
| June 2005 | - | $1.40 M(-88.6%) | $13.74 M(+11.4%) |
| Mar 2005 | - | $12.34 M | $12.34 M |
| Dec 2004 | -$10.30 M(+239.7%) | - | - |
| Dec 2003 | -$3.03 M | - | - |
FAQ
- What is Mirati Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Mirati Therapeutics?
- What is Mirati Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Mirati Therapeutics?
What is Mirati Therapeutics annual cash flow from investing activities?
The current annual CFI of MRTX is $225.80 M
What is the all time high annual CFI for Mirati Therapeutics?
Mirati Therapeutics all-time high annual cash flow from investing activities is $225.80 M
What is Mirati Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of MRTX is -$62.19 M
What is the all time high quarterly CFI for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly cash flow from investing activities is $195.15 M
What is Mirati Therapeutics TTM cash flow from investing activities?
The current TTM CFI of MRTX is $207.79 M
What is the all time high TTM CFI for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM cash flow from investing activities is $371.40 M